Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Clear all
Terminated Phase 1Phase 2 Interventional

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

NCT01234519
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
AEZS-108, AEZS-108 at MTD
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 30, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

RISE FOR HEALTH Study

NCT05365971
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

Functional Magnetic Micturition in Patients w/SCI

NCT00011557
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Assistance in Voiding
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 30, 2026, 6:47 AM EDT
Recruiting Phase 2 Interventional

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

NCT06733363
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 1 Bladder Cancer AJCC v8
Interventions
Behavioral Dietary Intervention, Telephone- Based Intervention
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Active, not recruiting Early Phase 1 Interventional

(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

NCT03837821
View directory record Official record
Conditions
Bladder Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Studies of Urinary Bladder Sensation

NCT00903435
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Quantitative Sensory Testing and Stimulus
Other
Lead sponsor
Timothy Ness, MD
Other
Eligibility
19 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

NCT03294304
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
Nivolumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 1 Interventional

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04440943
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 30, 2026, 6:47 AM EDT
Active, not recruiting No phase listed Observational

Exploring Clinical Utility of Wearables for the Bladder in Pelvic Health Physical Therapy Clinics

NCT07451106
View directory record Official record
Conditions
Postpartum Bladder Dysfunction, Post-prostatectomy Bladder Dysfunction, Bladder Dysfunction
Interventions
DFree Non-Invasive Bladder Ultrasound, Perifit Kegel Exerciser, Exit interview
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

NCT06586255
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Bladder Cancer
Interventions
Concurrent Immunotherapy and Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

NCT03129126
View directory record Official record
Conditions
Hemorrhagic Cystitis
Interventions
LP-10
Drug
Lead sponsor
Lipella Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 30, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 30, 2026, 6:47 AM EDT
Completed No phase listed Observational

Urology Database to Evaluate Clinical Information and Improve Patient Care.

NCT00376298
View directory record Official record
Conditions
Incontinence, Prostate Cancer, Interstitial Cystitis, Urinary Retention, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 30, 2026, 6:47 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS

NCT02550561
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Posterior Tibial Nerve Stimulation
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

NCT01938573
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions
Cisplatin, Gemcitabine Hydrochloride, Sirolimus, Cystectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 30, 2026, 6:47 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

NCT02141490
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Kidney Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging (MRI)
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Not applicable Interventional Results available

Use of the Leva Incontinence System in Treating Bladder Incontinence.

NCT03536923
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Leva Incontinence System For Pelvic Floor Muscle strengthening
Device
Lead sponsor
Renovia, Inc.
Industry
Eligibility
18 Years to 89 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Not applicable Interventional

Ambulatory Closed-loop Stimulation for Bladder Control

NCT05740527
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Noninvasive electrical stimulation of genital nerves
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 30, 2026, 6:47 AM EDT
Not listed No phase listed Observational

Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer

NCT06009510
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 30, 2026, 6:47 AM EDT
Completed Not applicable Interventional

A Study of Two Versions of the Uresta Pessary Handle for Women With Stress Urinary Incontinence

NCT07706491
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
pessary handle
Device
Lead sponsor
Resilia Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 6:47 AM EDT